|
| Friday, May 15, 2026 |
|
|
Substantial Shareholder Wei Fu Increases Shareholding in Everest Medicines Again, Marking His Second Share Purchase in 2026 and Demonstrating Long-term Confidence |
| Everest Medicines (HKEX: 1952.HK) announced that on 14 May 2026, based on strong confidence in the company's future prospects and long-term development, Mr. Wei Fu, a non-executive Director, the honorary chairman of the Board and a substantial shareholder of the company, purchased 660,000 ordinary shares of the company on the open-market for a total consideration of approximately HK$20.7 million, representing an average price of approximately HK$31.25 per Share. more info >> |
|
|
雲頂新耀主要股東傅唯再度增持 年內第二次加倉彰顯長期信心 |
| 雲頂新耀（HKEX 1952.HK）發佈公告，基於對公司未來前景及長遠發展的堅定信心，公司非執行董事、董事會榮譽主席兼主要股東傅唯先生於2026年5月14日通過公開市場購入公司普通股66萬股，並表示不排除在適當時候進一步增持。 more info >> |
|
|
云顶新耀主要股东傅唯再度增持 年内第二次加仓彰显长期信心 |
| 云顶新耀（HKEX 1952.HK）发布公告，基于对公司未来前景及长远发展的坚定信心，公司非执行董事、董事会荣誉主席兼主要股东傅唯先生于2026年5月14日通过公开市场购入公司普通股66万股，并表示不排除在适当时候进一步增持 more info >> |
|
| Wednesday, April 22, 2026 |
|
|
Everest Medicines Announces Positive First-in-Human Data for Personalized mRNA Cancer Vaccine EVM16 at AACR 2026 |
| Everest Medicines announced that the first-in-human (FIH) clinical trial data of EVM16, a proprietary personalized mRNA cancer vaccine, were presented at the 2026 American Association for Cancer Research 'Annual Meeting (AACR 2026). more info >> |
|
|
雲頂新耀mRNA個性化腫瘤治療性疫苗EVM16於AACR 2026公佈首次人體數據積極 展現良好安全性、較強免疫原性與初步療效 |
| 雲頂新耀宣佈在2026年美國癌症研究協會（AACR）年會上公佈其自主研發的mRNA個性化腫瘤治療性疫苗EVM16單藥治療及聯合PD-1抑制劑（替雷利珠單抗）治療晚期實體瘤的首次人體臨床試驗（FIH）數據。結果顯示出良好的安全性和耐受性、顯著的免疫原性及積極的初步療效信號，支持進一步臨床開發的推進 more info >> |
|
|
云顶新耀mRNA个性化肿瘤治疗性疫苗EVM16于AACR 2026公布首次人体数据积极 展现良好安全性、较强免疫原性与初步疗效 |
| 云顶新耀宣布在2026年美国癌症研究协会（AACR）年会上公布其自主研发的mRNA个性化肿瘤治疗性疫苗EVM16单药治疗及联合PD-1抑制剂（替雷利珠单抗）治疗晚期实体瘤的首次人体临床试验（FIH）数据。 more info >> |
|
| Monday, March 23, 2026 |
|
|
Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint |
| Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited (CORXEL). more info >> |
|
|
雲頂新耀達成艾曲帕米鼻噴霧劑資產收購協議 強化心血管領域產品佈局 |
| 雲頂新耀宣佈與箕星藥業香港有限公司（以下簡稱「箕星藥業」）達成資產收購協議 (The Asset Purchase Agreement)，獲得艾曲帕米（Etripamil）鼻噴霧劑（擬定中文商品名：星必妥(R)）在大中華區的開發、商業化及產品地產化權益。 more info >> |
|
|
云顶新耀达成艾曲帕米鼻喷雾剂资产收购协议 强化心血管领域产品布局 |
| 云顶新耀宣布与箕星药业香港有限公司（以下简称"箕星药业"）达成资产收购协议 (The Asset Purchase Agreement)，获得艾曲帕米（Etripamil）鼻喷雾剂（拟定中文商品名：星必妥(R)）在大中华区的开发、商业化及产品地产化权益。 more info >> |
|
| Wednesday, March 11, 2026 |
|
|
Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY(R) in Mainland China, Addressing Unmet Need in Moderately to Severely Active Ulcerative Colitis |
| Everest Medicines (1952.HK) announced the commercial launch of VELSIPITY(R) (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. According to reports, on the day the first prescription was issued in mainland China, VELSIPITY(R) was simultaneously prescribed in eight tertiary hospitals across seven key cities'Guangzhou, Shanghai, Hangzhou, Xi'an, Chongqing, Beijing, and Nanjing'achieving immediate coverage of patients in major regions nationwide on its launch day. more info >> |
|
|
|
|
